Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad201 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Kristen M Marks und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.
- Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- HIV-NAT, Thai Red Cross AIDS Research Centre and CE in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
- Division of Infectious Diseases, McGovern Medical School, University of Texas, Houston, Texas, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Marks, K. M., Kang, M., Umbleja, T., Avihingsanon, A., Sugandhavesa, P., Cox, A. L., Vigil, K., Perazzo, H., Price, J. C., Katsidzira, L., Vernon, C., Alston-Smith, B., Sherman, K. E., & ACTG 5379 Study Team (2023). Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad201
Vancouver
Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, et al. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad201
BibTeX
@article{Marks2023,
author = {Marks, Kristen M and Kang, Minhee and Umbleja, Triin and Avihingsanon, Anchalee and Sugandhavesa, Patcharaphan and Cox, Andrea L and Vigil, Karen and Perazzo, Hugo and Price, Jennifer C and Katsidzira, Leolin and Vernon, Christina and Alston-Smith, Beverly and Sherman, Kenneth E and ACTG 5379 Study Team, ACTG 5379 Study Team},
title = {Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad201}
}
EUVIMED